Literature DB >> 4045525

Radiotherapy as initial treatment for bulky stage II testicular seminomas.

S R Smalley, R G Evans, R L Richardson, G M Farrow, J D Earle.   

Abstract

Sixteen consecutive patients with bulky stage II seminoma were treated with primary radiotherapy from 1971 to 1982. Bulky stage II seminoma was defined as either Union Internationale Contre le Cancer (UICC) stage IIC (retroperitoneal metastases greater than 5 cm) or IID (palpable retroperitoneal metastases) with no evidence of visceral or supradiaphragmatic disease. The median age was 38 years (range, 26 to 52) and the median size of retroperitoneal disease was 11.5 cm (range, 5 to 25 cm). Patients were treated with generous radiation ports (such as wide hockey-stick or whole abdomen) often followed by boosts to the sites of bulky disease. Median tumor dose was 3,235 cGy (range, 2,700 to 5,668 cGy). Mediastinal (with or without supraclavicular) prophylactic radiation was administered to 15 of the 16 patients with a median dose of 2,590 cGy (range, 1,200 to 3,700 cGy). Treatment toxicity was mild. All 16 patients achieved a complete remission (CR) with radiotherapy. Median follow-up from the time of diagnosis was 60 months, and all patients are currently disease-free. Two patients recurred after therapy but were rendered disease-free with further radiation. These two relapsing patients have remained disease-free, following initial recurrence, for 8 years. The excellent results obtained with modern imaging and radiotherapeutic techniques justify radiotherapy as the initial treatment of choice for bulky stage II seminomas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045525     DOI: 10.1200/JCO.1985.3.10.1333

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  2 in total

1.  Testicular neoplasms: seminoma.

Authors:  E K Reddy; M Burke; S Giri; L Krishnan; L Gemer; R Evans; W K Mebust; J Wiegel
Journal:  J Natl Med Assoc       Date:  1990-09       Impact factor: 1.798

2.  Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

Authors:  S D Fosså; J P Droz; G Stoter; S B Kaye; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.